Alterations in mitochondrial homeostasis have been implicated in the etiology of Parkinson disease (PD) as demonstrated by human tissue studies, cell culture and in vivo genetic and toxin models. Mutations in the genes encoding PTEN-induced kinase 1 (PINK1), Omi/HtrA2 and parkin contribute to rare forms of parkinsonian neurodegeneration. Recently, each of these proteins has been shown to play a normal role in regulating mitochondrial structure, function, fission-fusion dynamics, or turnover (autophagy and biogenesis), promoting neuronal survival. Here, we review the biochemical mechanisms of mitochondrial protection conferred by each of these PD associated gene products in neurons, neuronal cell lines and other cell types. Potential molecular interactions and mitoprotective signaling pathways involving these three PD associated gene products are discussed in the context of mitochondrial quality control, in response to increasing levels of mitochondrial damage. We propose that PINK1, Omi/HtrA2 and parkin participate at different levels in mitochondrial quality control, converging through some overlapping and some distinct steps to maintain a common phenotype of healthy mitochondrial networks.
Introduction
Parkinson disease (PD) is a progressive and incurable disease that affects approximately 1% of the North American population. This devastating neurodegenerative disease is characterized by the progressive loss of dopaminergic neurons of the substantia nigra, with involvement of other neuronal populations resulting in autonomic and cognitive dysfunction. Motor symptoms in PD may not be apparent until the majority of dopaminergic neurons are lost (Betarbet et al. 2002) , most likely due to multiple compensatory mechanisms.
PD is a multifactorial disease for which the etiology in most cases remains unknown. While >90% of cases are sporadic, mutations in several nuclear encoded genes have been linked to the development of autosomal recessive and dominant familial parkinsonian syndromes (Bogaerts et al. 2008) , enhancing our understanding of biochemical and cellular mechanisms contributing to disease. Cell culture and mouse models that overexpress PD associated mutations or knockout versions of PD-implicated genes implicate alterations in mitochondrial biology, antioxidant defense mechanisms, the ubiquitin-proteasome pathway and autophagolysosome systems.
While human tissue, cybrid models and neurotoxin models of dopaminergic cell injury have long implicated mitochondrial pathobiology as a key mechanism in PD, the discovery of PTEN-induced kinase 1 as the gene mediating the PARK6 autosomal recessive locus added further impetus to this area of research (Valente et al. 2004) .
PINK1 is the first member of the large canonical serine/ threonine (Ser/Thr) protein kinases shown to be regulated by a canonical N-terminal mitochondrial targeting sequence [reviewed in (Mills et al. 2008) ]. Interestingly, other PD associated gene encoded proteins such as α-synuclein, LRRK2 and parkin show at least partial localization to mitochondria even though these proteins lack canonical mitochondrial targeting sequences (Darios et al. 2003; Biskup et al. 2006; Devi et al. 2008; Narendra et al. 2008 ). In the following sections, we will review evidence supporting the concept of impaired mitochondrial quality control as a point of convergence for multiple parkinsonian pathways, indicating a central role in PD pathogenesis.
The role of mitochondrial dysfunction in PD pathogenesis
Mitochondria play a central role in most eukaryotic metabolic processes by serving as the main generators of ATP, acting as calcium sinks for buffering intracellular calcium levels, and integrating multiple metabolic and apoptotic signaling pathways. Mitochondria are dynamic organelles that exhibit bidirectional movement with the capacity to undergo fragmentation (fission) and elongation (fusion). These processes regulate neuronal survival, stability of the mitochondrial genome, mitochondrial transport, synaptogenesis, and functional refilling of the neurotransmitter vesicle reserve pool (Karbowski and Youle 2003; Li et al. 2004; Verstreken et al. 2005; Lu 2009 ). Mitochondrial fission is also an important step for the autophagic clearance of depolarized or damaged mitochondria, as overexpression of the fission mediator Drp1 promotes mitophagy (Twig et al. 2008) .
There is growing consensus that mitochondrial dysfunction is a major contributor to the pathogenesis of PD. Midbrain dopaminergic neurons are particularly vulnerable to oxidative stress due to the oxidative nature of the dopamine metabolism, and their low mitochondrial reserve compared to other neuronal populations (Liang et al. 2007 ). In addition, the observation that exposure to certain mitochondrial complex I inhibitors recapitulates many symptoms of PD in humans and other mammalian species demonstrates a critical role of mitochondrial dysfunction in dopaminergic neuron dysfunction (Betarbet et al. 2002) . Our laboratory and others have shown that exposure to parkinsonian neurotoxins lead to generation of mitochondrial superoxide, mitochondrial fission and swelling, mitochondrial dysfunction, activation of mitochondrial pools of mitogen activated protein kinases, mitochondrial autophagy resulting in degradation of outer membrane and inner membrane localized proteins, and nuclear depletion of prosurvival transcription factors (Heikkila and Cohen 1973; Cassarino et al. 1999; Zhu et al. 2002; Chalovich et al. 2006; Kulich et al. 2007; Zhu et al. 2007; Dagda et al. 2008; Gomez-Lazaro et al. 2008 ). Most of the mitochondrial deficits induced by exposure to neurotoxins are recapitulated in loss-of-function culture models of PINK1, Parkin and human high temperature requirement protein A2 (Omi/ HtrA2) (Martins et al. 2004; Mortiboys et al. 2008; Dagda et al. 2009a, b; Flinn et al. 2009; Lutz et al. 2009 ), suggesting that PINK1, Parkin and Omi/HtrA2 normally function to promote maintenance of mitochondrial integrity.
Mitochondrial quality control pathways
The major mechanisms of mitochondrial quality control can be conceptualized in three major tiers. The first line of defense involves chaperones and prevention of mitochondrial injury and oxidative stress. The second involves localized degradation of damaged proteins by mitochondrial proteases, and ubiquitin-proteasomal degradation of certain outer membrane proteins (Tatsuta 2009; Tatsuta and Langer 2009) . The third pathway is activated by more severe dysfunction and involves fission-based sequestration and autophagic clearance of damaged mitochondria. Each of these quality control steps would also be dependent upon effective biogenesis of new mitochondrial components (Cherra and Chu 2008).
Since neurons are so highly dependent upon oxidative phosphorylation, it is likely that key regulators of mitochondrial quality control may regulate more than one of these tiers in order to effectively integrate cellular responses to achieve mitochondrial and neuronal homeostasis.
PD-linked genes: PINK1, HtrA2/Omi and parkin PINK1 was initially discovered to be mutated in two large consanguineous families of Spanish and Italian descent that were affected with early onset parkinsonism (Valente et al. 2004) . With the exception of the N-terminal mitochondrial targeting region, more than 50 mutations of PINK1 have been mapped throughout the kinase and C-terminal regulatory domains with differential effects on kinase activity and/or protein stability, strongly implicating a neuroprotective role for PINK1 [reviewed by (Mills et al. 2008) ]. Different in vitro kinase studies have shown that PINK1 contains some degree of ser/thr kinase activity towards casein and myelin basic protein, two commonly used in vitro kinase substrates [reviewed by (Cookson et al. 2007 )], although putative biological targets of PINK1 activity remain elusive.
